
JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(6), P. 962 - 964
Published: Dec. 1, 2024
Language: Английский
JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(6), P. 962 - 964
Published: Dec. 1, 2024
Language: Английский
Life, Journal Year: 2025, Volume and Issue: 15(2), P. 245 - 245
Published: Feb. 6, 2025
The introduction of anticancer agents has transformed oncology, significantly improving survival rates. However, these therapies have introduced unintended cardiovascular risks, with atherosclerovascular disease (ASCVD) emerging as a leading cause morbidity and mortality among cancer survivors. development ASCVD in this population involves multifactorial mechanisms, including endothelial dysfunction, oxidative stress, systemic inflammation, disrupted lipid metabolism. This review examines the various mechanisms through which chemotherapy contributes to highlights strategies for risk assessment management. Each class presents distinct challenges: anthracyclines induce stress damage, promoting foam cell formation plaque progression; taxanes vascular growth factor (VEGF) inhibitors impair metabolism stability; anti-metabolites exacerbate injury reactive oxygen species; mTOR inhibitors, hormonal therapies, tyrosine kinase immune checkpoint disrupt profiles inflammatory pathways, increasing rupture thrombosis. Mitigating chemotherapy-induced necessitates comprehensive, multidisciplinary approach. Detailed pre-treatment assessments must address traditional cancer-specific factors, demographics, pre-existing conditions, modifiable behaviors such smoking inactivity. Pharmacological interventions like statins angiotensin-converting enzyme (ACE) paired lifestyle modifications, are essential reducing risk. In resource-limited settings, cost-effective should be prioritized enhance accessibility. Establishing cardio-oncology units facilitates care coordination, while long-term surveillance enables timely detection intervention. These collectively improve outcomes survivorship diverse patient populations.
Language: Английский
Citations
0JACC CardioOncology, Journal Year: 2024, Volume and Issue: 6(6), P. 962 - 964
Published: Dec. 1, 2024
Language: Английский
Citations
0